ArticleNeurology2026
Retinal Optical Coherence Tomography-Angiography and Longitudinal Changes in Cognition and Cerebral Small Vessel Disease.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesCross-sectional studies suggest that retinal microvascular abnormalities measured by optical coherence tomography angiography (OCTA) are associated with cerebral small vessel disease (cSVD) and cognitive impairment, but longitudinal relationships remain unclear. We investigated whether OCTA measures are associated with brain cSVD markers and cognition over time and whether baseline OCTA was associated with brain and cognitive outcomes after mild ischemic stroke.
methodsWe conducted a prospective longitudinal cohort study recruiting patients with lacunar or mild cortical ischemic stroke (modified Rankin Scale ≤2) from a hospital stroke service. Participants underwent OCTA, brain MRI, and medical and cognitive assessment (MoCA) at baseline and 1 year. OCTA metrics included vessel density (VD), foveal avascular zone area, vessel radius, tortuosity, and flow index from superficial and deep vascular layers. MRI outcomes included white matter hyperintensity (WMH) volume, basal ganglia perivascular space (PVS) volume, and mean diffusivity in normal-appearing white matter. We used linear mixed-effects models to assess (1) whether retinal measures were associated with brain and cognitive markers over time and (2) whether baseline retinal measures were associated with 1-year outcomes, adjusting for age, sex, systolic blood pressure, smoking, diabetes, stroke severity, disability, and stroke subtype.
resultsA total of 189 participants (mean age 64.8 years; 37% female) were assessed at baseline and 154 at 1 year. Longitudinal reductions in retinal VD were associated with WMH increase (superficial layer, standardized β [95% CI] -0.045 [-0.067 to -0.023]; deep layer -0.050 [-0.074 to -0.026]). Increases in retinal VD and reductions in retinal flow were associated with increased PVS volume. Lower MoCA over 1 year tracked with decreases in deep retinal VD (0.136 [0.036-0.236]). Baseline retinal measures were associated with future outcomes: In particular, lower baseline VD in both layers was associated with worse MoCA at 1 year (superficial layer 0.125 [0.043-0.207]; deep layer 0.242 [0.162-0.322]). DISCUSSION: OCTA-measured retinal microvascular features are associated with cSVD progression and worsening cognition after mild stroke, while baseline OCTA was associated with future brain and cognitive outcomes. These findings suggest that OCTA holds promise as a noninvasive tool for monitoring retinal microvascular pathology in stroke populations enriched for cSVD, warranting further investigation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.